Bleomycin
- Generic Name
- Bleomycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C55H84N17O21S3
- CAS Number
- 11056-06-7
- Unique Ingredient Identifier
- 40S1VHN69B
- Background
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
- Indication
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
- Associated Conditions
- Hodgkin's Lymphoma, Malignant Pleural Effusion, Non-Hodgkin's Lymphomas, Squamous Cell Carcinoma (SCC), Teratocarcinoma, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma
- Associated Therapies
- Palliative Treatment
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01060904
- Locations
- 🇺🇸
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 19
- Registration Number
- NCT00993512
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- Copenhagen University Hospital at Herlev
- Target Recruit Count
- 98
- Registration Number
- NCT00918593
- Locations
- 🇩🇰
Copenhagen University Hospital at Herlev, Herlev, Copenhagen, Denmark
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT00654732
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT00577993
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Rituximab and ABVD for Hodgkin's Patients
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 85
- Registration Number
- NCT00504504
- Locations
- 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2018-08-27
- Target Recruit Count
- 51
- Registration Number
- NCT00369681
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT00352027
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
- Conditions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 65
- Registration Number
- NCT00284271
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
HD12 for Advanced Stages
- Conditions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- University of Cologne
- Registration Number
- NCT00265031
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.